Michael Slade, MD, Washington University School of Medicine, St Louis, MO, discusses the use of salvage second autologous stem cell transplantation (autoSCT) in the era of novel cellular and antibody-based therapies for multiple myeloma. Dr Slade explains that whilst the use of this treatment is decreasing, several retrospective analyses have shown a benefit for specific subsets of patients and are suggesting that a longer period of time before a second autoSCT could lead to better outcomes. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.